Skip to main content
. 2022 Nov 23;12:1005626. doi: 10.3389/fonc.2022.1005626

Figure 1.

Figure 1

Italian (A) and Sicilian (B) trend of ADR reports related to TKIs approved for NSCLC over the years. ADR, adverse drug reaction; NSCLC, non-small cell lung cancer; TKIs, tyrosine kinase inhibitors.